Zoledronic acid is effective for reducing hip fracture risk among postmenopausal women with osteoporosis. Zoledronic acid is effective for reducing hip fracture risk among postmenopausal women with ...
Zoledronic acid and denosumab demonstrated comparable fracture and mortality outcomes among patients with type 2 diabetes and osteoporosis. Zoledronic acid and denosumab demonstrate comparable ...
In this analysis, 3 bisphosphonates (alendronate, pamidronate, and zoledronic acid) and 1 RANK ligand inhibitor (denosumab) were evaluated for their effectiveness at preventing osteoclasts from ...
Treatment with zoledronic acid (Zometa) before onset of skeletal morbidity may lower the risk of skeletal-related events (SRE) and prolong the time to the first SRE in men with bone metastases from ...
SEATTLE — Among bariatric surgery patients treated with denosumab to counter bone loss, follow-up treatment with zoledronic acid prevented the rebound effect on markers of bone turnover that is ...
How to Optimize Physicians’ Communication Skills in Cancer Care: Results of a Randomized Study Assessing the Usefulness of Posttraining Consolidation Workshops Purpose: To assess the efficacy and ...
Compared with oral bisphosphonates, denosumab reduced fracture risk among treatment-experienced postmenopausal women with osteoporosis. Treatment with denosumab vs oral bisphosphonates is associated ...
SCHAUMBURG, Ill.--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Zoledronic Acid Injection, USP in ...
Medicare covers the injectable drug, Reclast, when a doctor deems it medically necessary for the treatment and prevention of osteoporosis. There are specific eligibility criteria, including having ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results